Adalimumab (Humira®) is the third TNF antagonist (after infliximab and etanercept) to be approved in the US. Like infliximab and etanercept, adalimumab binds to TNFα, preventing it from activating TNF receptors; adalimumab was constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein. TNFα inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases. As of Jan 2006, adalimumab has been approved for the treatment of rheumatoid arthritis and psoriatic arthritis, and data have been submitted to the FDA for expanding the label to include the treatment of plaque psoriasis. Other possible indications are likely to include those in which infliximab or etanercept have already been tested in and/or approved for, including ankylosing spondylitis and Crohn's disease.

Humira is marketed in preloaded 0.8 ml syringes and is injected subcutaneously, typically by the patient at home. It cannot be administered orally, because the digestive system would destroy the drug.

Humira's manufacturer is Abbott Laboratories.

Lawsuit

---

In March 2003, British company Cambridge Antibody Technology (CAT), stated its wish to "initiate discussions regarding the applicability of the royalty offset provisions for Humira" Abbott Laboratories in the High Court of London. In November 2004, the trial began. In December 2004, the Judge, Justice Laddie Ruled for CAT stating "Abbott was in error when it made its first royalty payment to CAT calculated on the basis that only 2% of the Net Sales was due. It should have calculated on the basis of the full royalty of just over 5% and should have paid and continued to pay CAT accordingly." Abbott later paid CAT $23.7 million.

More on [ Adalimumab ]

Adalimumab - Twitter Search

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis ... - http://bit.ly/8xiceg - RT
MediaTower (Media Tower) Sat, 12 Dec 2009 18:22:52 -0000
Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis ... - http://bit.ly/8xiceg - RT
Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis ... - http://bit.ly/8xiceg
WorldNewsEU (News Stories) Sat, 12 Dec 2009 18:22:33 -0000
Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis ... - http://bit.ly/8xiceg
abatacept vs adalimumab head-2-head http://bit.ly/8TENZW
paidtrials (US Clinical Trials) Thu, 10 Dec 2009 23:26:55 -0000
abatacept vs adalimumab head-2-head http://bit.ly/8TENZW
@MedicalNewsNet, FDA Reviews Safety Data on Abatacept, Adalimumab for Juvenile Idiopathic Arthritis, by @elizmech http://bit.ly/4DUZSy
joycefr (Joyce Frieden) Wed, 09 Dec 2009 22:39:19 -0000
@MedicalNewsNet, FDA Reviews Safety Data on Abatacept, Adalimumab for Juvenile Idiopathic Arthritis, by @elizmech http://bit.ly/4DUZSy
for @MedicalNewsNet, FDA Reviews Safety Data on Abatacept, Adalimumab for Juvenile Idiopathic Arthritis, by @elizmech http://bit.ly/4DUZSy
hsplete (Heidi Splete) Wed, 09 Dec 2009 21:58:25 -0000
for @MedicalNewsNet, FDA Reviews Safety Data on Abatacept, Adalimumab for Juvenile Idiopathic Arthritis, by @elizmech http://bit.ly/4DUZSy
Crohn's Disease Information: NICE recommends infliximab and adalimumab for the treatment of ... http://bit.ly/5hMoW9
nahjam (Natahs Jaime) Wed, 09 Dec 2009 07:38:43 -0000
Crohn's Disease Information: NICE recommends infliximab and adalimumab for the treatment of ... http://bit.ly/5hMoW9

Subscribe to Adalimumab RSS feed